Back to School: How biopharma can reboot drug development. Access exclusive analysis here

OxThera: A two-for-one offer

By concentrating on two forms of a single indication for which no therapeutics are available and few are in development, OxThera AB is hoping to corner the Orphan market for primary hyperoxaluria and maintain a role in the larger secondary hyperoxaluria indication.

Primary hyperoxaluria is a rare genetic disease affecting about 2,000 patients in the U.S. and Europe, resulting

Read the full 597 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers